Collaboration and License Agreements - Narrative (Details) - USD ($)			1 Months Ended			3 Months Ended			12 Months Ended
	May 26, 2021	Dec. 26, 2020	Jul. 31, 2021	Dec. 31, 2020	Apr. 30, 2020	Sep. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions							$ 0
Cost share advance							104,178,000				$ 121,862,000
Amounts due to Pfizer							11,025,000				1,954,000
Due from collaborators							100,000,000				0
Deferred revenue							70,491,000	$ (23,333,000)
Pfizer collaboration revenue							29,509,000	0
Cost share advance from Pfizer							(18,285,000)	0
Shared costs							$ 18,285,000
Richter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received included in current deferred revenue												$ 40,000,000.0
Maximum payment from regulatory milestones achieved													$ 40,000,000.0
Additions to deferred revenue					$ 10,000,000.0
Maximum payment from sales-related milestones achieved													$ 107,500,000
Decrease in contract liability from regulatory milestones achieved								$ 33,300,000
Percentage of performance obligation satisfied							66.66%
Richter | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Decrease in contract liability from regulatory milestones achieved			$ 15,000,000.0
Richter | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions to deferred revenue						$ 15,000,000.0
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment from regulatory milestones achieved		$ 100,000,000.0
Additions to deferred revenue	$ 100,000,000.0
Maximum payment from sales-related milestones achieved		$ 3,500,000,000
Upfront payment received				$ 650,000,000.0
Percentage of revenue recognized		100.00%
Maximum payment from milestones achieved		$ 3,700,000,000
Maximum aggregate payment from milestones achieved		200,000,000.0
Option exercise fee		$ 50,000,000.0
Percent of costs covered by counterparty		100.00%
Additions		$ 150,000,000.0
Repayment period		2 years
Reduction in cost share advance from implied financing costs		$ 3,600,000
Deferred revenue, recognition period		6 years
Amounts due to Pfizer							$ 11,000,000.0				1,900,000
Amounts due to collaboration partner, share of profits							$ 5,800,000				$ 1,800,000
Percentage of revenue recognized by counterparty							50.00%				50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses							$ 5,200,000				$ 100,000
Pfizer collaboration revenue							29,500,000
Cost share advance from Pfizer							(17,700,000)
Shared costs							18,300,000
Amortized deferred financing costs							600,000
Pfizer | R&D expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amounts due to collaboration partner, reimbursement of allowable expenses							400,000
Shared costs							7,600,000
Pfizer | SG&A expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amounts due to collaboration partner, reimbursement of allowable expenses							4,800,000
Shared costs							10,200,000
Pfizer | Collaboration Expenses
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs							$ 500,000
Pfizer | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received			100,000,000.0
Decrease in contract liability from regulatory milestones achieved			$ 100,000,000.0
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company									$ 50,000,000.0	$ 100,000,000.0